The introduction of Retatrutide ZPHC, at a concentration of 120mg, is sparking considerable buzz within the healthcare community. This novel dual GIP and GLP-1 agonist medication suggests to provide impressive improvements in body shedding compared to current therapies. Preliminary clinical studies have demonstrated substantial declines in body fat